COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Yang, M. C. [1 ]
Tan, E. C. H. [1 ]
机构：
[1] Natl Taiwan Univ, Taipei 10764, Taiwan
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.110
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN19
引用
收藏
页码：A736 / A736
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer
    Georgieva, M.
    Aguiar, P., Jr.
    Lima, J. P.
    Haaland, B.
    Lopes, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2148 - S2149
  • [2] Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
    Georgieva, Mina
    da Silveira Nogueira Lima, Joao P.
    Aguiar, Pedro
    Lopes, Gilberto de Lima, Jr.
    Haaland, Benjamin
    [J]. LUNG CANCER, 2018, 124 : 248 - 254
  • [3] Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer
    Yang, Szu-Chun
    Ou, Huang-Tz
    Su, Wu-Chou
    Wang, Shi-Yi
    [J]. CANCER MEDICINE, 2023, 12 (07): : 8838 - 8850
  • [4] Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Wielage, Ron
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Lawson, Anthony
    Schwartzberg, Lee
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) : 1263 - 1272
  • [5] Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Wielage, Ron
    Schwartzberg, Lee
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : 1404 - 1414
  • [6] COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, C. W.
    Lang, H. C.
    [J]. VALUE IN HEALTH, 2019, 22 : S165 - S166
  • [7] The potential cost-effectiveness of first-line immunotherapy plus chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).
    Roth, Joshua A.
    Trung Nguyen
    Goulart, Bernardo H. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer
    Shu, Yamin
    Ding, Yiling
    Li, Feie
    Zhang, Qilin
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 114
  • [9] MOLECULAR SCREENING IN ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSES FOR FIRST-LINE THERAPY
    Zaim, Remziye
    Thunnissen, Erik
    Dingemans, Anne-Marie
    Postmus, Pieter E.
    Uyl-De Groot, Carin A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S604 - S605
  • [10] The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
    Lu, Tingting
    Huang, Yufan
    Cai, Zhongjie
    Lin, Wangchun
    Chen, Xiaoxiao
    Chen, Ruijia
    Hu, Yingying
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
12345